Our science

Throughout 13 years of Selvita operations, we’ve had the opportunity to execute a variety of exciting and complex projects for our Clients.
The nature of our business is based on high degree of trust and confidentiality, however we are always very excited to co-author or contribute to scientific publications which present our work.

Whenever possible we publish and present materials such as journal publications, posters, case studies or technical notes, aiming to show the scope of experience of our scientific team.
In the section below, you can find the continuously updated information on our recent publications.

Our science

Blog

Go to blog

Case studies

More case studies

Webinars

Search by keyword
Regulatory Services
    Analytical outlook for biosimilar development
    Magdalena Bielak-Łakomska
    Magdalena Bielak-Łakomska Associate Director in Analytics Selvita S.A.
    Jan Smagur
    Jan Smagur Director of Cell and Molecular Biology Laboratory Selvita S.A.
    Krzysztof Stawujak
    Krzysztof Stawujak Business Development Manager Selvita S.A.

    The variability and complexity of biological medicines compel extensive and comprehensive characterization studies to ensure safety and efficacy. Compared to small-molecule drugs, structural and functional characterization of biologics can be a tedious and challenging process. It involves using state-of-the-art technologies to evaluate the purity, specificity, potency, and toxicity, all in accordance with international regulatory guidelines. During the webinar, Selvita’s Experts intend to characterize regulatory requirements and provide an outlook for analytical approaches for biosimilar development and manufacturing process changes.

    The webinar will feature a discussion between some of Selvita’s most experienced scientific team members: Magdalena Bielak-Łakomska, Associate Director in Analytics, and Jan Smagur, Director of Cell and Molecular Biology Laboratory, moderated by Krzysztof Stawujak, Business Development Manager.

    Duration 1:00 Starting on April 29, 2021, 15:00 CEST
    Drug Discovery
      A discussion on modern small molecule drug discovery
      Tom Coulter, PhD
      Tom Coulter, PhD Integrated Drug Discovery Director
      Przemyslaw Zawadzki, PhD
      Przemyslaw Zawadzki, PhD Director of Medicinal Chemistry
      Piotr Graczyk, PhD
      Piotr Graczyk, PhD Scientific Director
      Anna Karawajczyk, PhD
      Anna Karawajczyk, PhD Head of Computational Chemistry

      This webinar will feature a discussion between some of Selvita’s most experienced scientific team members, on selecting small molecule modalities to address protein targets in drug discovery. The debate will highlight areas of experience and recommendations for planning approaches for new projects. Dr. Anna Karawajczyk, Head of Computational Chemistry, will moderate a discussion of Dr. Tom Coulter, Integrated Drug Discovery Director, Dr. Przemyslaw Zawadzki, Director of Medicinal Chemistry and Dr. Piotr Graczyk, Scientific Director.

      Duration 1 hour Date 16:02, 03 February 2021

      Presentations

      Go to presentations

      Poster presentations

      Poster icon
      26 August 2020 LC/HRMS ORBITRAP Technique - Essential tool in drug development process
      Download presentation

        The download link has been sent to the e-mail address.
        Poster icon
        07 July 2020 Cloning and Expression Platform for Production of Recombinant Proteins
        The poster describes the cost and time-effective Selvita platform for cloning and E. coli expression (which is only one of our platforms for expression).
        Download presentation

          The download link has been sent to the e-mail address.
          Poster icon
          07 July 2020 A short synthesis of Dronedarone
          Selvita’s chemists are adept at designing enhanced approaches to target molecules and in this poster and paper illustrate how they collaborated on a synthesis of the atrial fibrillation drug Dronedrone which has been reworked to more than half the number of synthetic steps using efficient and environmentally friendly chemistry.
          Download presentation

            The download link has been sent to the e-mail address.
            Go to poster presentations

            Publications

            Poster icon
            Mitogenic activity and proliferative effect of a New-developed short acting Insulin analogue Human insulin analogues with modified amino acid sequence may exert stronger proliferative effect and carcinogenic potential than insulin itself. The objective of the study was to assess mitogenic activity and activation of proliferation in tumorigenic and non-tumorigenic cell lines upon stimulation with a new-developed short-acting B28Lys-B29Pro human insulin (KP) in comparison to EU Pharmacopeia human insulin standard (HIS) and insulin AspB10 with strong mitogenic, cancerogenic activity. Find out more
            Go to publications

            Technical notes

            Development of an in vitro assay of neurodegeneration using human pluripotent stem cell–derived neurons

            Human induced pluripotent stem cells (hiPSC) are obtained by genetically reprogramming somatic cells from human tissues, after which these cells can be further differentiated virtually into any cell types. hiPSC are derived from normal adults or from diseased patients and carry protein mutations that are able to compromise the cell physiology.

            As consequence, hiPSC-derived cells reveal a high potential for studying pathophysiological processes in basically all pathological areas including CNS, PNS, peripheral tissues (cardiac, hepatic, pulmonary, muscular, vessel, blood, etc.)…

            Find out more
            Go to technical notes

            Contact form

              According to the Regulation 2016/679 of the European Parliament and the Council (EU) of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation; "GDPR"), we hereby inform you that Your personal data will be processed by Selvita S.A. and the companies operating within the Selvita Capital Group in order to present You the Selvita Newsletter. Your personal data are processed in connection with Newsletter subscription and in order to keep You informed about all events taking place in Selvita Capital Group.

              We guarantee full transparency of the data processing and compliance with all the rights referred to in GDPR, i.e. the right of access, rectification and deletion of data, limiting data processing, the right to transfer, the right to raise objection against processing. Notwithstanding the above, You have the right to submit a complaint to the supervisory authority. Your personal data are not being subject to automated decision-making, including profiling. Your personal data are provided on the voluntary basis, however please be informed that lack of consent results in inability to provide You the Newsletter by Selvita Group. Your data will be processed for the duration of your consent, unless your consent to the processing of your personal data is revoked. Your consent may be withdrawn at any time by sending a request to the e-mail address: gdpr@selvita.com.

              For more information on how Selvita handles personal data please visit: Privacy Policy. I hereby express my consent to the processing of my personal data by Selvita S.A. with registered office in Cracow 30-348, Bobrzyńskiego 14 and its affiliated companies in order to receive the Newsletter, information about events organized by the Selvita Capital Group and other information regarding Selvita Group activity in accordance with the Regulation 2016/679 of the European Parliament and the Council (EU) of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation).